Brainsway (BWAY)
(Delayed Data from NSDQ)
$5.40 USD
+0.05 (0.93%)
Updated May 24, 2024 04:00 PM ET
After-Market: $5.35 -0.05 (-0.93%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.40 USD
+0.05 (0.93%)
Updated May 24, 2024 04:00 PM ET
After-Market: $5.35 -0.05 (-0.93%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
Zacks News
Molecular Diagnostics Sales to Drive Hologic (HOLX) Q3 Earnings
by Zacks Equity Research
Hologic's (HOLX) Q3 performance will likely benefit from the increased utilization of Panther instruments and contributions from its recent acquisitions.
What's in Store for Thermo Fisher (TMO) in Q2 Earnings?
by Zacks Equity Research
The emergence of the new virus variants, through the months of Q2, is likely to have led to top-line contributions within Thermo Fisher's (TMO) Life-Science Solutions segment.
What's in Store for Boston Scientific (BSX) in Q2 Earnings?
by Zacks Equity Research
Within the PI business of Boston Scientific (BSX), Q2 sales are expected to have been strong, banking on the strong performance of the drug-eluting franchise.
Wall Street Analysts Believe Brainsway Ltd. Sponsored ADR (BWAY) Could Rally 159%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 158.6% in Brainsway Ltd. Sponsored ADR (BWAY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Brainsway Ltd. Sponsored ADR (BWAY) Stock Jumps 9.4%: Will It Continue to Soar?
by Zacks Equity Research
Brainsway Ltd. Sponsored ADR (BWAY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
BrainsWay (BWAY) is in Overbought Territory: What's Next?
by Zacks Equity Research
BrainsWay (BWAY) has moved higher as of late, but there could definitely be trouble on the horizon for this company
Brainsway Ltd. Sponsored ADR (BWAY) Moves 10.6% Higher: Will This Strength Last?
by Zacks Equity Research
Brainsway Ltd. Sponsored ADR (BWAY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Should You Buy BrainsWay (BWAY) Ahead of Earnings?
by Zacks Equity Research
BrainsWay (BWAY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
STERIS (STE) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
STERIS (STE) is likely to have continued to gain from the robust demand of PPE and COVID-19-related products in Q4.
Strength Seen in Brainsway Ltd. Sponsored ADR (BWAY): Can Its 7.3% Jump Turn into More Strength?
by Zacks Equity Research
Brainsway Ltd. Sponsored ADR (BWAY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
AngioDynamics (ANGO) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
AngioDynamics (ANGO) witnessed revenue growth across two business segments in fiscal Q1.
NEOGEN (NEOG) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
NEOGEN's (NEOG) segmental revenues improve for the fiscal first quarter on strong sales of cleaners, disinfectants and sanitizers.
Brainsway's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Brainsway.
Brainsway (BWAY) Jumps: Stock Rises 7.5%
by Zacks Equity Research
Brainsway (BWAY) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Company News for Aug 25, 2020
by Zacks Equity Research
Companies in the news are: ZM, AXAS, CGIX, BWAY
What's in Store for GW Pharmaceuticals (GWPH) in Q1 Earnings?
by Zacks Equity Research
GW Pharmaceuticals (GWPH) might have registered slower international sales growth from procedural deferrals due to coronavirus pandemic in Q1.